Devil's claw

Quick links to important sections

Devil's claw

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Devil's claw

Quick Facts: Devil's Claw

Property Description
Active ingredient Harpagoside (an iridoid glycoside)
Form Capsules, Tablets, Tinctures, Gels
Pharmacological class Phytomedicine, Anti-inflammatory agent
General purpose Support for joint pain and musculoskeletal discomfort
Origin Botanical, from the root of Harpagophytum procumbens

What Kind of Medicine is Devil's Claw? (Classification and Origin)

Devil's claw (Harpagophytum procumbens) is a Phytomedicine and Herbal remedy derived from the concentrated dried root extract of a plant native to southern Africa. It is fundamentally classified as a Natural product of botanical origin. Its medicinal identity is primarily linked to its high-level pharmacological class as both an Anti-inflammatory agent and an Analgesic agent. Preparations based on Harpagophytum procumbens are used for relieving minor joint pain, an application supported by pharmacological studies. This role involves supporting flexibility and comfort.


What is Devil's Claw Made of and How is it Prepared? (Composition and Forms)

The therapeutic characteristics of Devil's claw are chiefly attributed to its primary active ingredient, Harpagoside, which belongs to the chemical group of iridoid glycosides. Medicinal preparations are based on a standardized single-ingredient extract from the secondary storage roots, ensuring consistency in the level of the active marker compound. Clinical trials of Devil's claw generally focus on standardized preparations containing a specified amount of Harpagoside. This consistent standardization approach differentiates Devil's claw from non-standardized herbal teas, emphasizing reliable delivery of the key component. The extract is commonly formulated for oral administration as capsules or tablets, but it is also available in liquid tinctures and topical bases, such as gels.


What is the General Purpose of Devil's Claw? (High-Level Benefit)

The core purpose of Devil's claw is to assist in moderating general musculoskeletal discomfort, such as the minor aches and stiffness that accompany aging or light physical strain. It functions by providing both an overall anti-inflammatory effect and an inherent anti-nociceptive effect (pain signal reduction). This dual mechanism is the basis for its application in supporting mobility and easing the general perception of pain, making it a valuable option particularly for those seeking a natural product alternative in managing chronic rheumatic conditions.

Regulatory References

  1. Harpagophyti radix - herbal medicinal product

What side effects are possible with Devil's claw?

Possible Side Effects and Safety Information

The use of Devil's claw (Harpagophytum procumbens) is generally considered possibly safe for most adults when taken orally for a limited duration, such as up to 12 weeks. However, its use carries several officially documented safety considerations and risks.

Adverse Reactions

Adverse reactions are primarily mild and commonly affect the Gastrointestinal System. Reported side effects include diarrhea, nausea, vomiting, abdominal pain, and indigestion. Central Nervous System effects, such as headache and vertigo (dizziness), have also been reported. Hypersensitivity reactions, which include allergic skin reactions, rash, and facial swelling, are uncommon.

Contraindications and Warnings

Devil's claw is contraindicated in certain patient groups and conditions due to known risks:

  • Active Peptic Ulcer Disease: Avoid use, as the product may stimulate the production of stomach acid, potentially worsening gastric or duodenal ulcers.
  • Pregnancy and Lactation: Use during pregnancy is not recommended as it is considered possibly unsafe; its use during breastfeeding should also be avoided due to a lack of safety data.
  • Paediatric Use: Use in children and adolescents under 18 years of age is not recommended as safety has not been established.

Caution is advised for individuals with:

  • Gallstones: Devil's claw may increase bile production, which could be problematic.
  • Heart and Circulatory Conditions: The preparation may affect blood pressure, heart rate, and heart rhythm.
  • Diabetes: It may affect blood sugar levels, necessitating careful monitoring.

Drug Interactions

Devil's claw may interact with certain medications. Of particular concern are agents that affect blood clotting, such as warfarin (Coumadin), as concurrent use may increase the risk of bleeding or bruising. It may also interfere with certain medications metabolized by liver enzymes (Cytochrome P450 substrates) or those that reduce stomach acid (e.g., H2-blockers, Proton Pump Inhibitors).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Devil's Claw (Harpagophytum procumbens) regarding overexposure is primarily defined by the absence of specific clinical data in regulatory documentation.

Overdose Scope Summary Official Regulatory Statement
Documented Manifestations No specific clinical symptoms or manifestations of overdose are formally documented in the official labeling.
Emergency Action Individuals are officially directed to seek emergency medical attention or contact a Poison Control Center right away if suspected ingestion significantly exceeds the recommended dose.

Official Overdose Statements:

  • No specific symptoms or clinical signs of overdose are formally documented in the official regulatory monographs for Devil's Claw preparations. This status reflects the absence of specific toxicity reports in official regulatory reviews.
  • In the event of suspected substantial overexposure, the primary mandated action is to seek emergency medical help immediately.
  • The required management approach is officially stated to be symptomatic and supportive treatment, as the regulatory documents confirm that no specific antidote is known for overexposure to the plant extract.
  • Hospital monitoring and observation may be required following clinical assessment of the quantity ingested.
  • No specific warnings or considerations regarding a difference in overdose risk or severity for sub-populations (e.g., pediatric or geriatric patients) are formally documented in the overdose sections reviewed.

Connection to the Overall Overdose Profile: The profile is structured around the regulatory finding that no specific overdose manifestations are known or documented in official labeling. Consequently, the government-mandated response focuses on procedural safety: requiring immediate help-seeking and defining treatment as strictly symptomatic and supportive, constrained by the fact that no specific antidote is known to exist.

Therapeutic Uses of Devil's claw

What Devil's Claw Supports: Main Uses and Benefits

Devil's claw (Harpagophytum procumbens) is commonly used for managing symptoms related to physical discomfort, particularly related to symptoms of increased neurological or muscular activity. The primary application of this herbal medicine is for the supportive relief of symptoms that become more disruptive during flare-ups, such as minor joint pain. Its use is focused on conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed.

Preparations of Devil's claw root are traditionally used for the relief of minor joint pain and are also relevant for easing symptoms related to systemic imbalance, such as those that interfere with daily functioning. This supportive approach contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable. This application centers on helping with symptoms of minor joint pain and supporting general well-being during symptomatic phases.


Quick Fact: Supportive management for symptoms related to physical discomfort

Regulatory References

  1. Harpagophyti radix - herbal medicinal product

Eligibility and Restrictions for Use

Who Can and Cannot Use Devil's Claw?

The population eligibility for using preparations of Devil's claw (Harpagophytum procumbens) is strictly defined by regulatory guidelines, primarily classifying users as adults and placing specific limitations on use in other populations.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults and the Elderly (age 18 and older).
Populations for whom use is not recommended Children and adolescents under 18 years of age.
Populations for whom use is contraindicated Patients with Active Gastric or Duodenal Ulcers.

Official Eligibility Statements

  • Use is Contraindicated in individuals with a known Hypersensitivity to the active substance or any component of the preparation.
  • It is Contraindicated for patients with active Gastric or Duodenal Ulcers.
  • The medicine is Not Recommended for Children and Adolescents under 18 years, as safety and efficacy have not been established in this age group.
  • Use is Not Recommended during Pregnancy or Lactation (Breastfeeding), as safety has not been established due to insufficient data.
  • Patients with Gallstones or cholelithiasis must consult a physician before using the medicine.

Official regulatory documents thus limit the use of Devil's claw to adults and the elderly, establishing clear prohibitions for patients with peptic ulcers or hypersensitivity. Use is discouraged in minors, pregnant women, and breastfeeding women due to the official status of "use not established."

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents and high-level government health summaries for Devil's Claw (Harpagophytum procumbens) identify potential interaction patterns based on the extract's known pharmacological profile. These interactions are defined across pharmacodynamic and pharmacokinetic mechanisms.


Pharmacodynamic Interactions

Co-administration with anticoagulants (e.g., warfarin) is documented as having the potential to increase the effects of these medicines, raising the chance of bruising or bleeding. Conversely, taking Devil's Claw might potentially decrease the effects of acid-reducing medicines, such as Proton Pump Inhibitors (PPIs) and H2-blockers.

Metabolic and Transporter Interactions

Devil's Claw has the documented potential to affect the body's processing of other medicines. This involves potential pharmacokinetic interactions with substrates of the major Cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C9, and CYP2C19. Alteration of these metabolic pathways could change how quickly the liver breaks down co-administered medicines. Furthermore, the potential to affect the cellular pumps known as P-glycoprotein (P-gp) is also noted, which could impact drug levels in the body.

Regulatory Context

Official regulatory labeling for Devil's Claw does not formally list any medicine combinations as universally contraindicated, nor does it specify mandatory requirements for timing separation of doses. All statements describe potential interaction patterns based on documented pharmacological activity.

Mechanism of Action

Modulating Inflammatory Gene Expression

This mechanism involves the extract's components, notably Harpagoside, interfering with the AP-1 transcription factor to suppress the gene expression of key inflammatory enzymes like COX-2 and various cytokines. This molecular interference acts as a preemptive signal to reduce the creation of pro-inflammatory proteins, resulting in a modulation of the inflammatory signal cascade.


Attenuation of Eicosanoid Synthesis

The suppression of the COX-2 enzyme production directly results in a significant reduction in the synthesis of Prostaglandin E2 ( PGE2), a powerful mediator in the eicosanoid pathway. The physiological consequence of lowering PGE2 concentrations is the decreased sensitization of peripheral nociceptors (pain-sensing nerves), which in turn attenuates peripheral nociceptive signaling.


Phytocomplex Synergy and Multi-Targeting

The full mechanistic efficacy of the extract relies on a phytocomplex synergy, where Harpagoside works alongside other components to target multiple points in the inflammatory cascade simultaneously. This multi-target approach ensures a broader, coordinated modulation of inflammation and influences feedback regulation within inflammatory pathways.

Dosage and Administration Information

How Devil's Claw Preparations Are Administered

The usage of Devil's Claw (Harpagophytum procumbens root extract) follows established administration principles. The preparation is generally designated for oral ingestion, predominantly in the form of capsules or film-coated tablets, although tinctures and topical gels are also available routes.

Dosing and Schedule

Feature Official Use Principle
Standard Daily Dose Generally up to 2.4 grams of the standardized dried root extract for symptomatic relief.
Frequency Administration involves divided use, typically taken two or three times daily to maintain consistent levels of the active components.
Administration Method Solid forms must be swallowed whole with water; they should not be crushed or chewed, and some traditional instructions suggest intake before meals.

Procedural Constraints and Duration

Devil's claw is intended for short-term use. If symptoms persist or worsen after approximately four weeks of use for minor articular discomfort, consultation with a healthcare professional is advised. Furthermore, use is not recommended for children and adolescents under 18 years of age due to insufficient data supporting safe administration in these age groups. Older adults typically follow the standard adult dosing regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Devil's Claw


Evidence for Use in Chronic Low Back Pain

Research has examined Devil's claw in studies involving individuals with outcomes related to physical discomfort, specifically chronic, non-specific low back pain. The majority of studies relevant in trials assessing short-term or episodic symptom patterns were conducted for this indication in short-term, randomized controlled trials (RCTs), where studies monitored responses over defined time intervals. These trials often used a placebo or an active drug comparator to see if there were measurable differences between the groups.

The studies monitored changes in symptom intensity, typically through standardized pain scales, and recorded how frequently participants needed to use rescue pain medication. Research also explored functional measurements to see how outcomes reflecting daily functioning or activity level changed. Studies report how symptoms evolved in the observed populations, and some higher-quality trials data show patterns related to measured symptom scores when compared to placebo over the short observation period.

However, research describes certain limitations in the available evidence base for this condition. The follow-up durations were limited, with most rigorous studies lasting only four to eight weeks. Therefore, long-term effects are not fully established, and it is unclear if any observed patterns persist after stopping use. Additionally, comparative evidence is lacking against many conventional treatments for back pain.


Evidence for Use in Osteoarthritis

Devil's claw was evaluated in research settings for conditions characterized by fluctuating or episodic manifestations, such as mild-to-moderate osteoarthritis (OA) of the hip or knee. The available evidence includes both short-term RCTs and observational studies. These trials monitored outcomes related to systemic or functional imbalance, using standardized tools like the WOMAC index to assess pain, stiffness, and overall joint function.

Studies explored the enrolled adult populations over defined time intervals to see how outcomes related to daily functioning or activity level evolved. The data for OA findings indicate variability and heterogeneity. Research describes changes measured during the study period in terms of patient-reported outcomes describing perceived discomfort and mobility scores. Findings were mixed across various systematic reviews, and the overall evidence quality varies across studies.

It is not yet clear whether observed short-term changes translate into sustained, long-term outcomes for those with OA. Sample sizes were modest in many trials, which can limit the certainty of the findings. Furthermore, data for certain groups remain insufficient, especially regarding patients with more advanced stages of OA.


Long-Term Data and Follow-Up

The majority of studies focusing on episodes where symptoms become more noticeable involving Devil's claw have focused on observation periods of less than six months. This means that clinical trials contribute to the broader evidence landscape by showing responses over defined, short time intervals.

Long-term outcomes are not well characterized. Research provides insight into short-term changes but limited information regarding the durability of any measured changes or the effects of continuous use over extended periods. While some observational studies have recorded data for up to six months, this duration is still considered intermediate for chronic conditions where symptoms may vary in intensity.


Evidence in Specific Populations

Most widely available clinical trials for Devil's claw was evaluated in generally healthy adult populations. The results apply only to the populations studied and cannot be assumed to apply to all groups.

Data for certain groups remain insufficient or non-existent in the published literature. For example, there is limited information derived from research involving children, adolescents, or pregnant populations. Also, while studies include adults, there is limited specific research examining how outcomes may differ in older adults or those who are managing complex comorbid health conditions.


What Research Gaps Remain Unfilled

Despite the existence of several clinical trials, because the follow-up durations were limited in many studies, the data provide limited information for long-term outcomes in the management of chronic conditions.

Furthermore, comparative evidence is lacking between Devil's claw and many other non-prescription or prescription options for pain management. This absence of direct comparative trials means comparative evidence is lacking. Lastly, evidence quality varies across studies, meaning synthesizing the full body of research requires careful consideration of the methodological differences between individual trials.

Frequently Asked Questions (FAQ)

Common questions about Devil's claw (FAQ)

Q: Is Devil's claw used for pain relief or is it only for inflammation?

Official regulatory indications and studies support the use of Devil's claw for the relief of minor joint pain and for its anti-inflammatory effects. The evidence suggests it provides both a reduction in inflammation and a component of pain signal modulation (an analgesic effect). Therefore, it is supported for use targeting both inflammation and associated discomfort.


Q: Are there traditional uses of Devil's claw that differ from its modern applications?

Yes. While modern regulatory indications focus on musculoskeletal conditions, traditional uses cited in official documents also include helping to stimulate appetite. It has also been cited in traditional contexts for relieving mild digestive upset and indigestion.


Q: Does Devil's claw help with all kinds of joint discomfort, or only certain types?

The main established uses confirmed by regulatory indications are for relieving minor joint pain associated with osteoarthritis and for chronic, non-specific low back pain. Official labels do not universally specify use for all other joint discomforts. Studies have primarily focused on outcomes related to physical discomfort in these specific areas.


Q: Can Devil's claw be used to relieve general muscle soreness?

Official indications generally focus on joint and back discomfort. However, regulatory references do state its use for general musculoskeletal discomfort, which can encompass muscle issues. It is important to note that specific studies confirming its use for temporary muscle soreness outside of conditions like osteoarthritis are often considered unproven in regulatory summaries.


Q: Is Devil's claw considered a natural alternative to common non-prescription pain relievers?

Devil's claw is classified as a Phytomedicine, or Herbal remedy, derived from a natural botanical source. Clinical trial summaries cited by authoritative health bodies have examined the response to Devil’s claw relative to that of some non-steroidal anti-inflammatory drugs (NSAIDs) for back pain.


Q: Is the extract used in supplements the same as the whole dried plant material?

No, they are not typically the same. Regulatory documents define the preparations as various forms of extracts or powdered root. Dosing is often standardized to ensure a consistent minimum level of the active marker compound, Harpagoside, which differs from simply using the non-standardized whole dried plant material.


Q: Is Devil's claw used for problems other than joint health and mobility?

Yes, official regulatory documents also list traditional use for mild digestive disorders, such as bloating or flatulence. It is also traditionally used to help with a temporary loss of appetite.


Q: Do people take Devil's claw for conditions like tension headaches?

No, relief of headache is not listed as an established or officially supported indication for Devil's claw. In fact, headache is documented in the official safety information as a potential adverse reaction or side effect.


Q: How long does it usually take to notice effects after starting Devil's claw?

Regulatory guidance suggests that Devil's claw has a slow onset of action. For conditions like osteoarthritis, official information specifies a duration of use of at least two to three months was examined in studies to observe beneficial effects.


Q: Is Devil's claw something that needs to be taken continuously for its effect to be maintained?

Regulatory documents generally define the product for short-term use, indicating it is not necessarily intended for indefinite continuous use. If a user's discomfort or symptoms persist or worsen after the defined period of use (such as four weeks), official documents indicate that consultation with a healthcare professional is instructed.


Q: Does the perceived effect of Devil's claw last all day?

Regulatory guidance often specifies the product to be taken in divided daily doses (two or three times per day). This schedule is designed to maintain consistent levels of the active ingredients in the body, which implies that the effect of a single dose may not last a full day.


Q: Is it non-directive to stop using Devil's claw once comfort is restored?

Regulatory documents provide specific guidance on when to consult a physician—namely, if symptoms persist or worsen after a period of use. The official information does not contain guidance regarding the non-directive decision to discontinue use after relief has been achieved.


Q: Are allergic reactions to Devil's claw possible, and what do they look like?

Yes, official safety information documents that hypersensitivity reactions are possible. These reactions may manifest as common symptoms like a rash or hives (urticaria). More serious documented signs can include swelling of the face.


Q: Are there any signs of excessive intake of Devil's claw?

There is limited specific human data available on toxicity or overdose symptoms. However, excessive intake would likely lead to an exaggerated presentation of the known common or severe side effects. The potential signs observed may be an exaggeration of the known common or severe side effects.


Q: Are there any restrictions for people who have existing kidney or liver conditions?

Official warnings and cautions focus on the potential for interaction with certain liver enzymes, such as the Cytochrome P450 group, and official safety information lists a specific caution for individuals who have gallstones. No formal contraindications are listed for general chronic kidney or liver disease.


Q: Does taking Devil's claw with food affect how it is absorbed?

Traditional administration instructions are sometimes noted in regulatory contexts and suggest taking the preparation before meals. However, regulatory documents typically focus on administration details like swallowing the preparation whole with water, and they do not provide explicit data on how food affects absorption or overall efficacy.


Q: Is the current research evidence for Devil's claw considered strong or limited?

Regulatory overviews summarize that the research base is characterized by variable quality and certain limitations. Studies are often short-term, and there are noted gaps concerning long-term use and direct comparisons to many other common treatments for pain management.


Q: Does the preparation method affect how well Devil's claw works?

Regulatory guidance dictates that products must be standardized to contain a consistent, specified level of the active marker compound, Harpagoside. This standardization aims to ensure consistent delivery and intended effects across different preparation methods, such as capsules versus tinctures.


Q: How does the quality and standardization of Devil's claw products vary by brand?

Standard-setting bodies require products to meet minimum active content thresholds, such as for Harpagoside. However, regulatory authorities recommend that consumers verify product sourcing, as the actual quality or standardization of some marketed supplements may vary or be inaccurate.

How should Devil's claw be stored and disposed of?

How to Store and Dispose of Devil's Claw

Storage and disposal requirements for Devil's claw preparations are defined by regulatory labeling to maintain product stability and integrity.


Storage Requirements

  • Temperature: Certain capsule and tablet formulations must be stored Do not store above 25°C (77°F).
  • Protection: The product must be stored in a cool dry place and the container should be kept tightly closed to protect from moisture and maintain shelf-life.
  • Container Integrity: Do not use the product if the packaging is broken or punctured.
  • Child Safety: All products must be stored Keep out of the sight and reach of children.

Disposal Instructions

  • Product-Specific: Topical patches are intended for single use and must be dispose of patch after single use.
  • General Disposal: Unused or expired products should be disposed of in accordance with local regulations for non-hazardous pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Devil's claw found in:

A-Z Index: